Clinical Trial Update: Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of dalotuzumab (MK-0646) in advanced solid tumors and multiple myeloma completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Dalotuzumab (dalotuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumor, Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2017-03-21